Chromovitrectomy in Vitreous Loss During Cataract Surgery by Taiji Sakamoto & Toshio Hisatomi
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Chromovitrectomy in  
Vitreous Loss During Cataract Surgery 
Taiji Sakamoto1 and Toshio Hisatomi2 
1Department of Ophthalmology,  
Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima,  
2Department of Ophthalmology,  
Kyushu University Graduate School of Medicine, Fukuoka,  
Japan 
1. Introduction 
Cataract surgery is the commonest surgical operation performed throughout the world, but 
surgery has always involved some risk. For example, vitreous loss (vitreous breaching the 
posterior capsule) associated with capsular rupture is a complication that significantly 
affects postoperative visual acuity. Direct and immediate effects of vitreous loss involve 
deviation of the pupil (corectopia), inflammation of the anterior chamber, corneal damage, 
and intraocular pressure elevation; indirect and late effects are cystoid macular edema, 
vitreous inflammation, and retinal detachment [1-6]. 
Various factors have been reported to associated with this complication [1]. There is no 
doubt that the skill of the surgeon is a major factor, and other predisposing factors include 
white cataract, small pupil, pseudoexfoliation, and a history of previous intraocular surgery. 
When lost vitreous is treated improperly, it can cause secondary complications, resulting in 
poor final visual acuity. To prevent these secondary harmful results, good knowledge, 
experience, and skill are required from surgeons. Specifically, complete removal of the 
vitreous from the anterior chamber is essential for a favourable postoperative outcome after 
posterior capsule rupture. However, the surgical procedure for removing the vitreous is 
difficult because the structure appears transparent under an operating microscope. The 
vitreous body in the anterior chamber is sometimes difficult even for an experienced 
surgeon to identify because the cornea is often damaged incidentally in cases involving 
vitreous prolapse, which are by definition complex cases.  
To facilitate this procedure, several approaches have been applied to improve visualisation 
of lost vitreous. A vital dye has generally been used to stain the lens capsule in standard 
cataract surgery. This technique is adopted to visualize lost vitreous. Another approach is to 
stain the components of the vitreous body directly. Recently, triamcinolone acetonide (TA) 
has been used as an adjunct to visualize the vitreous body during pars plana vitrectomy 
(PPV) [7]. This technique was originally developed to visualize the vitreous body on the 
retinal surface. Moreover, it was found to be very helpful for elucidating the 
pathophysiology of the vitreous body in various retinal diseases [8-10]. Therefore, it has 
been a natural step to adopt this technique to stain the vitreous in an attempt to facilitate its 
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removal in cases of a ruptured capsule during cataract surgery. The following section 
presents the concepts behind this methods as well as technical details. 
2. History of visualization of the vitreous body 
Modern closed vitreous surgery owes much to the work of Machemer [11]. After initial 
success vitrectomy continued to be developed and has now been established as a standard 
treatment for vitreoretinal diseases. With advances in instrumentation and understanding of 
vitreoretinal pathophysiology the indications for vitrectomy have been expanded to include 
a variety of diseases such as simple rhegmatogenous retinal detachment, macular hole, and 
macular oedema [8]. In the early days of its use vitrectomy was performed for diseases in 
which the vitreous body was visible due to vitreous hemorrhage, proliferative diabetic 
retinopathy, and asteroid hyalosis. At present though indications for vitrectomy include 
eyes with optically clear vitreous such as in macular hole surgery, and removing transparent 
hyaloid and/or internal limiting membrane (ILM) has become a standard procedure. 
Despite advances in surgical instrumentation and techniques, the vitrectomy procedure 
continues to demand both skill and experience. Removing the vitreous is a particularly 
challenging procedure, partly due to its transparency. Various approaches have been taken 
to assist in visualisation of the vitreous during vitrectomy. Recently, intraoperative 
triamcinolone acetonide has been used in many countries worldwide [7,8].  
In the earliest years of retinal surgery, it was recognized that vital dyes could be helpful for 
facilitating surgery. In such cases, the structure of the vitreous was not the main target, so 
dyes such as Indian ink, methylene blue and fluorescein were used primarily to visualise 
retinal breaks. This vital staining was not so commonly used in surgery at that time; 
however, recently it has been revived as chromovitrectomy. Visualizing ILM is being 
studied extensively and chromovitrectomy is now one of the most important elements of 
vitreous surgery.  
 In terms of the macroscopic structure of the vitreous, important work has been done using 
cadaveric eyes and living eyes with biomicroscopy or optical coherence tomography (OCT) 
examinations; the results have contributed extensively to our understanding of the 
pathology of vitreoretinal diseases [12-14]. Unfortunately, observational techniques cannot 
be applied during surgery, thus valuable information cannot be fully used during surgery in 
individual cases, especially during surgical manoeuvres, though of note intraoperative OCT 
is starting to be used by some surgeons. Abrams et al noticed in the early days of vitrectomy 
that staining of the vitreous with fluorescein dye improved the ease of vitrectomy by 
facilitating clear visualization of the vitreous, although this method was used only in 
animals and for surgical training [15]. Some 20 years later, it was proven in a report which 
showed that preoperative fluorescein angiography or orally administered sodium 
fluorescein stained a transparent vitreous, making it visible as light green [16,17]. However, 
thin posterior hyaloids could not be visualized well by this method, which is indispensable 
in modern surgery on the retinal surface such as for macular hole or pre-retinal membrane. 
On the other hand, intravitreous application of autologous blood was used for a similar 
purpose [18]. It was reported that intravitreous autologous blood could identify the 
posterior vitreous cortex and facilitate surgical manoeuvres with reduced complications. 
However, blood is not transparent so it is not necessarily helpful to remove ILM. 
Furthermore, unclotted erythrocytes may become lysed in the irrigation fluid and swirl the 
liberated haemoglobin in the vitreous cavity, obscuring the fundus view with a dusty 
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appearance. This characteristic prevents autologous blood from being commonly used in 
vitrectomy. 
3. Visualization of vitreous during cataract surgery 
Although vitreous loss is a significant complication of cataract surgery, the outcome can 
be almost as good as if it had not happened when managed properly - though there 
nevertheless remains an increased risk of retinal break and retinal detachment. Needless 
to say, the first and most important step is early recognition that vitreous loss has taken 
place. The second step is to evaluate the loss of vitreous properly with or without using 
an anterior vitrector. For that purpose, at present there are the several approaches as 
described below. 
3.1 Trypan blue 
Trypan blue has been reported to be effective for staining tissue during anterior and 
posterior segment surgery without significant toxicity to corneal endothelial cells with short 
exposure times [19]. In a preliminary study, the dye was injected into the anterior chamber 
under an air bubble, which prevents dilution of the trypan blue and avoids direct contact 
between the undiluted dye and the endothelium. Subsequently, the dye was removed with a 
vitreous cutter as vitrectomy proceeded. On the first postoperative day no residual staining 
was visualized on inspection with a slit lamp and ophthalmoscope, and no side effects 
related to intraoperative use of the dye were observed in any patient. This technique was 
applied to visualize prolapsed vitreous in cataract surgery [20]. Trypan blue does not stain 
vitreous body directly, but rather allows visualization of the vitreous body by staining the 
surrounding tissues such as iris and lens capsule. So far there have been no reports on the 
apparent toxicity of trypan blue in intracameral use [21].  
3.2 Triamcinolone acetonide and other related materials 
In Japan triamcinolone acetonide (TA) is now the most commonly used agent for pars plana 
vitrectomy (PPV) for visualization of a transparent vitreous body. A national survey in 
Japan showed that 75% of PPV comprised TA-assisted PPV in 2005 [22]. When intravitreous 
TA was first used for PPV, there were strong concerns about its potential adverse effects 
such as glaucoma, endophthalmitis, or direct toxicity related to preservatives [8]. However, 
the incidence of these potential adverse events were not significant, probably as most of the 
TA crystals were removed at the end of surgery [8]. This safety issue was partly supported 
by the fact that intravitreous injection of TA (without removal) did not cause serious or 
profound adverse events [23].  
Unlike other vital dyes, white granules of TA adhere to the surface of the vitreous, which 
clearly shows the margin of the vitreous [24,25]  This is also the case with intracameral use 
of TA. Even a small amount of TA can be of great help in visualizing even traces of vitreous 
in the anterior chamber with a surgical microscope (Figure 1). Theoretically, TA crystals 
should be removed as much as possible at the end of surgery, because steroid granules left 
in the anterior chamber might induce secondary glaucoma or infection. But, it might not be 
necessary because an intracameral depot to release dexamethasone is left safely in the 
anterior chamber after cataract surgery [26]. In addition, it is impossible in practice to 
remove all the granules from the anterior chamber.  
 











The posterior capsule is ruptured and the vitreous body is moved into the anterior chamber; 
triamcinolone is sprayed at the location where the vitreous body is likely to have been placed, using a 
syringe with a dull-edged needle. The vitreous body immediately appears as a white-coloured gel. The 
vitreous body with TA crystals (arrows) were then easily removed with a vitreous cutter. Arrowhead 
indicates optic of intraocular lens (A and B). Reprinted from: Yamakiri K et al. (2004), with permission 
from Elsevier [25]. 
Fig. 1. Intraoperative photograph of triamcinolone-assisted vitrectomy (cataract surgery 
after rupture of lens capsule).  
A novel approach related to use of TA will be described. Kaji et al reported a new technique 
for visualising the vitreous in the anterior chamber using 11-deoxycortisol (11-DC) [27]. Its 
suspension can be prepared without the antiseptic and emulsifying agents contained in 
commercially available TA. A precursor of cortisol in the cascade of steroid metabolism, 11-
DC, is naturally detectable in blood and urine. This material is free from glucocorticoid and 
mineralocorticoid actions. In addition, the conversion system of 11-DC into cortisol is not 
present in ocular tissues. Thus, 11-DC injected into the anterior chamber does not induce 
steroid-related complications such as ocular hypertension. As for the molecular structure, 
11-DC contains hydroxyl groups, thus it has some hydrophilic characteristics. Therefore, 11-
DC left in the anterior chamber is easily cleared and excreted through the urine. In their 
study, there were white particles on the surface of the iris or in the vitreous body on the day 
following surgery, but all the particles had completely disappeared within 2 days after 
surgery [27]. This hydrophilic characteristic of 11-DC is highly advantageous over 
hydrophobic cholesterol as a tool to visualize the vitreous body.  
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There are however concerns about use of 11-DC. Under some circumstances, the steroid 
activity of TA is advantageous to reduce post-operative inflammation, which 11-DC does 
not have. The particle size of 11-DC is larger than that of TA. Above all, 11-DC is not 
commercially available in most of countries at present. Although the use of TA in cataract 
surgery was off-label, there is a product of TA for general medical use (e.g. Kenalog made 
by Bristol-Myers Squibb) and products which are licensed specifically for intraocular 
conditions have also been licensed (e.g. Trivaris made by Allergan). Consequently, TA can 
be used more easily and in theory more safely than 11-DC. This is a major obstacle to more 
widespread use of 11-DC.  
In an experimental study, Yamashita et al demonstrated that polylactic acid could be 
applied for this purpose [28]. Polylactic acid is a biodegradable substance without any 
biological effects. In 2004, the U.S. Food and Drug Administration approved a poly-L-lactic 
acid (PLLA)–based injectable medical device for restoring and/or correcting signs of facial 
fat loss in people with human immunodeficiency virus. As a result, the properties of PLLA 
microparticles have attracted considerable interest in the medical community. PLLA 
granules are originally white and adhere to the gel-like structure of the vitreous body so 
easily that they assist in visualizing the transparent vitreous as do TA granules but with no 
harmful consequences in rabbits and nonhuman primates. In future this agent might be a 
good alternative in cases where TA is proven to be intolerably harmful such as ocular 
steroid-responders at risk of glaucoma.  
4. Possible adverse events  
Although chromovitrectomy is very helpful for facilitating the removal of vitreous in the 
anterior chamber, to our knowledge there has been no large-scale comparative study. The 
incidence of vitreous loss in cataract surgery is low and this complication is not predictable 
[29], therefore it is not possible to conclusively describe any role for chromovitrectomy in 
preventing adverse events. However, possible adverse events can be described from the 
results of animal studies, small studies, or chromovitrectomy for vitreoretinal diseases. 
4.1 Trypan blue and other vital dyes 
At present indocyanine green, trypan blue, and brilliant blue G are commonly used for 
capsular staining in cataract surgery. Of these, trypan blue has been deemed safe for clinical 
use [30]. However, non-infectious endophthalmitis has been reported after intracameral use 
of trypan blue in cataract surgery [31]. In an in vitro study, trypan blue has been shown to 
be toxic to human corneal endothelial cells at high concentrations or with long exposure 
[32]. In an animal study conducted by the authors, intracameral injection of each dye 
resulted in corneal damage to a certain extent and trypan blue was most toxic (Figure 2) [33]. 
The results of in vitro or animal studies may not necessarily reflect clinical conditions 
correctly; however, this information should be noted when using trypan blue. Therefore, 
trypan blue should be removed as much as possible at the end of surgery. The use of trypan 
blue in cataract surgery does not increase intraocular pressure, nor cause infectious 
endophthalmitis, or retinal detachment [34].  
Most importantly, it should be remembered that these dyes are used in potentially inflamed 
and/or damaged tissues. The safety issue should be considered more seriously than usual 
and great caution is warranted. 
 








Brown Norway rats received intracameral injection into each eye and the eyes were examined with 
electron microscopy after 2 months. In the brilliant blue G (BBG) groups, the ultrastructure of the 
corneal cells and collagen cellular matrix were well preserved (10 mg/mL). The indocyanine green 
(ICG) group showed mitochondrial swelling at the 5-mg/mL concentration. The trypan blue (TB) group 
showed cyst formation in the endothelial cell layer due to separation of the cells and degeneration of the 
corneal endothelium in a sporadic manner (original magnification x6600). The BBG–exposed corneas 
demonstrated a normal hexagonal endothelial cell sheet with intact borders and no endothelial 
swelling. The ICG group showed cellular swelling and some degenerated cells in the corneal 
endothelial cells. C, In the TB group, endothelial cell shrinkage was recognized in a sporadic manner. 
Cell shrinkage led to endothelial cell loss in the central area of the cornea (original magnification x1000). 
The detailed method was described by Hisatomi et al [33]. 
Fig. 2. Ultrastructure of rat corneal cells studied using transmission electron microscopy and 
scanning electron microscopy.  
4.2 Triamcinolone and related materials 
Corticosteroids are known to have several adverse effects on an eye, thus this issue was of 
particular concern from the beginning. However, most of the results have been obtained 
from the intravitreous use of TA. These should be interpreted carefully. 
Corticosteroids are strong inducers of intraocular pressure (IOP) rise. Recent studies have 
revealed that intravitreous TA without vitrectomy causes a significant rise of IOP in more 
than 50% of eyes [23]. In comparison, the incidence of IOP rise was not high after TA-
assisted vitrectomy, probably due to the fact that TA crystals were almost totally removed at 
the end of surgery. The largest-scale controlled trial showed that 23 out of 391 eyes (5.9%) 
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had a significant IOP rise in TA-assisted vitrectomy; while 13 out of 383 eyes (3.4%) did so in 
conventional vitrectomy, a difference which did not reach statistical significance [35]. Most 
of these rises in intraocular pressure could be managed with topical treatment, but some of 
them required filtration surgery [8,35]. It should be noted that patients who had a history of 
glaucoma were not included in these studies. Because a history of glaucoma is a risk factor 
for an intraocular hypertensive response to corticosteroid, care must be taken when using 
TA in patients with such a history. 
Corticosteroid has an immune-suppressive effect and endopthalmitis has a poor visual 
prognosis, thus postoperative infection has been the foremost concern in the intraoperative 
use of TA. The incidence of acute endophthalmitis was reported to be 7/26,819 cases 
(0.026%) in the Japan national survey [22]. Therefore, it is not as high as that of simple 
intravitreous TA injection (0.87%) described by Moshfeghi et al and is similar to the 
incidence of 20 gauge vitrectomy without TA (0.018 to 0.05%) [36].  
The toxicity of TA suspension has been reported in an experimental study. Direct exposure 
to preserved TA in rabbits damaged the corneal endothelial cells probably due to the 
preservative benzyl alcohol [37,38]. To avoid potential toxicities, it is preferable to use 
preservative-free TA. In most cases, decantation of preservative prior to injection is 
considered to be sufficient to avoid potential toxicity. At present, if necessary, benzyl 
alcohol-free TA is commercially available (TriesenceTM, Alcon, Ft Worth, Tx, USA) or 
(MacuaidTM, Wakamoto, Tokyo, Japan).  
5. Chemovitrectomy in the future: To see is to believe! 
Although cataract surgery is one of the safest procedures in ocular surgery, there is always 
some risk attached. No surgery can be free from risk, thus every effort has to be made to 
reduce risk in surgery. Vitreous loss is a significant risk of cataract surgery, but proper 
treatment can prevent further complications ensuing from loss of vitreous. Visualization of 
vitreous is the key challenge to surgeons trying to provide optimal technical outcomes in 
such cases, which can be greatly facilitated by chromovitrectomy. Although the present vital 
dyes or TA may be replaced by better agents in the future, the concept of chromovitrectomy, 
“visualizing vitreous,” will remain as long as vitrectomy is performed. 
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